Q3 2020 Sales Performance

New R&D approach will support the development of current clinical portfolio From Spend spread thinly across too many programmes ("shots on goal" strategy) Consensus-driven decision making R&D/Commercial silos Limited Business Development activity Science X Technology Culture To Backing the best assets, gsk and removing those that don't look promising Culture of accountability where smart risk-taking and courageous decisions are made by individuals and rewarded Robust governance model with scientific peer review, commercial input and data-driven decisions Leveraging Business Development to optimise our portfolio 44

View entire presentation